Advanced Cell Technology to Participate at the Marcus Evans ''Facing Stem Cell Research Challenges'' Conference, June 8-9, 2006.ALAMEDA, Calif. -- Advanced Cell Technology, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ACTC ACTC Apple Certified Technical Coordinator ACTC Almaden Cycle Touring Club ACTC Associated Colleges of the Twin Cities ACTC All Ceylon Tamil Congress (Sri Lanka) ACTC Association Canadienne de Télévision par Câble ) will participate at the Marcus Evans "Facing Stem Cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. Research Challenges" Conference at the Hyatt Regency, San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation). The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] . In his keynote presentation on Friday, June 9th, at 9:45 a.m., Michael D. West Dr. Michael D. West is an entrepreneurial scientist and visionary [1] [2] [3] [4] who has led progress in anti-aging and biotechnology. He is CEO of BioTime, Inc. , Ph.D., Chairman, President and Chief Scientific Officer, will discuss strategies for the accelerated development of therapeutics from human embryonic stem cells Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. ES cells are pluripotent. . Dr. West will also discuss the Company's ACTCellerate technology platform which was unveiled earlier this week at the European Stem Cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young & Regenerative Medicine Conference 2006 in London, and show data on the first new differentiated cells derived using the technology, designated ACTC60. Human embryonic stem cells (hESC) are the first cells cultured in the laboratory capable of becoming every cell type in the human body. Therefore, the emerging field of regenerative medicine holds great promise for the treatment of many currently untreatable Un`treat´a`ble a. 1. Incapable of being treated; not practicable. diseases. Despite that potential, researchers have not previously demonstrated efficient means of producing a large array of therapeutically-useful cell types in a pure and scalable form that allows them to be tested for potential human therapeutic use. The Company's proprietary ACTCellerate platform was invented by the Company as a means of accelerating the differentiation of cells from human embryonic stem cells, thereby expanding potential products made from embryonic stem cell technology. Dr. West's presentation will be available for viewing at the Company's web site http://www.advancedcell.com/conference-presentations/. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California Alameda is a city in Alameda County, California, United States. It is located on a small island of the same name next to Oakland, California in the San Francisco Bay. An additional part of the city is Bay Farm Island, which is adjacent to the Oakland International Airport. and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion